Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 694

1.

High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C.

Nephrol Dial Transplant. 2009 Sep;24(9):2792-6. doi: 10.1093/ndt/gfp191. Epub 2009 Apr 25.

PMID:
19395730
2.

Risk factors for higher mortality at the highest levels of spKt/V in haemodialysis patients.

Salahudeen AK, Dykes P, May W.

Nephrol Dial Transplant. 2003 Jul;18(7):1339-44.

PMID:
12808171
3.

Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients.

Hsu SP, Pai MF, Peng YS, Chiang CK, Ho TI, Hung KY.

Nephrol Dial Transplant. 2004 Feb;19(2):457-62.

PMID:
14736974
4.

Chronic inflammation and mortality in haemodialysis: effect of different renal replacement therapies. Results from the RISCAVID study.

Panichi V, Rizza GM, Paoletti S, Bigazzi R, Aloisi M, Barsotti G, Rindi P, Donati G, Antonelli A, Panicucci E, Tripepi G, Tetta C, Palla R; RISCAVID Study Group.

Nephrol Dial Transplant. 2008 Jul;23(7):2337-43. doi: 10.1093/ndt/gfm951. Epub 2008 Feb 27.

PMID:
18305316
5.

Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.

Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M.

Nephrol Dial Transplant. 2010 Aug;25(8):2672-9. doi: 10.1093/ndt/gfq053. Epub 2010 Feb 18.

PMID:
20172849
6.

Predictors of mortality in long-term haemodialysis patients with a low prevalence of comorbid conditions.

De Lima JJ, Sesso R, Abensur H, Lopes HF, Giorgi MC, Krieger EM, Pileggi F.

Nephrol Dial Transplant. 1995;10(9):1708-13.

PMID:
8559493
7.

Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients.

Okuno S, Ishimura E, Kohno K, Fujino-Katoh Y, Maeno Y, Yamakawa T, Inaba M, Nishizawa Y.

Nephrol Dial Transplant. 2009 Feb;24(2):571-7. doi: 10.1093/ndt/gfn521. Epub 2008 Sep 17.

PMID:
18799606
8.

Fibroblast growth factor 23 and matrix-metalloproteinases in patients with chronic kidney disease: are they associated with cardiovascular disease?

Peiskerová M, Kalousová M, Kratochvílová M, Dusilová-Sulková S, Uhrová J, Bandúr S, Malbohan IM, Zima T, Tesar V.

Kidney Blood Press Res. 2009;32(4):276-83. doi: 10.1159/000243050. Epub 2009 Oct 1.

9.

Is there any survival advantage of obesity in Southern European haemodialysis patients?

Chazot C, Gassia JP, Di Benedetto A, Cesare S, Ponce P, Marcelli D.

Nephrol Dial Transplant. 2009 Sep;24(9):2871-6. doi: 10.1093/ndt/gfp168. Epub 2009 Apr 15.

PMID:
19369686
10.

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.

Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M.

N Engl J Med. 2008 Aug 7;359(6):584-92. doi: 10.1056/NEJMoa0706130.

11.

Association of mineral metabolism with an increase in cellular adhesion molecules: another link to cardiovascular risk in maintenance haemodialysis?

Arici M, Kahraman S, Gençtoy G, Altun B, Kalyoncu U, Oto A, Kirazli S, Erdem Y, Yasavul U, Turgan C.

Nephrol Dial Transplant. 2006 Apr;21(4):999-1005. Epub 2005 Dec 2.

PMID:
16326734
12.

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M.

J Am Soc Nephrol. 2005 Jul;16(7):2205-15. Epub 2005 May 25.

13.

The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients.

Phelan PJ, O'Kelly P, Walshe JJ, Conlon PJ.

Ren Fail. 2008;30(4):423-9. doi: 10.1080/08860220801964236.

PMID:
18569917
14.

Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis.

Fukuoka K, Nakao K, Morimoto H, Nakao A, Takatori Y, Arimoto K, Taki M, Wada J, Makino H.

Nephrology (Carlton). 2008 Jun;13(4):278-83. doi: 10.1111/j.1440-1797.2007.00864.x.

PMID:
18476915
15.

The association of lipid levels with mortality in patients on chronic peritoneal dialysis.

Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS.

Nephrol Dial Transplant. 2006 Oct;21(10):2881-92. Epub 2006 May 30.

PMID:
16735386
16.

Mild hyperphosphatemia and mortality in hemodialysis patients.

Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P.

Am J Kidney Dis. 2005 Jul;46(1):68-77.

PMID:
15983959
17.

Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.

Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M.

Am J Kidney Dis. 2004 Sep;44(3):481-7.

PMID:
15332221
18.

The impact of diabetes mellitus on vitamin D metabolism in predialysis patients.

Tanaka H, Hamano T, Fujii N, Tomida K, Matsui I, Mikami S, Nagasawa Y, Ito T, Moriyama T, Horio M, Imai E, Isaka Y, Rakugi H.

Bone. 2009 Nov;45(5):949-55. doi: 10.1016/j.bone.2009.07.016. Epub 2009 Jul 23.

PMID:
19631779
19.

Serum phosphate levels and mortality risk among people with chronic kidney disease.

Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL.

J Am Soc Nephrol. 2005 Feb;16(2):520-8. Epub 2004 Dec 22.

20.

Relation between serum urea and mortality of hemodialysis patients.

Stosovic M, Stanojevic M, Simic-Ogrizovic S, Jovanovic D, Djukanovic Lj.

Ren Fail. 2009;31(5):335-40.

PMID:
19839831

Supplemental Content

Support Center